国家科技图书文献中心 杭州服务站
首页
资源导航
特色服务
知识发现
关于我们
检索
代查代借

检索历史
浏览历史

订阅
收藏
0 申请单

个人中心
账号设置
充值
全部 |
  • 全部
  • 题名
  • 作者
  • 机构
  • 关键词
  • NSTL主题词
  • 摘要
检索 二次检索 AI检索
高级检索
外文文献 中文文献
筛选条件：

共搜索到388条信息
?

1. Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial NSTL国家科技图书文献中心

Francesco Cosentino |  Samuel Dagogo‐Jack... -  《Diabetes, obesity & metabolism.》 - 2025,27(2) - 583～594 - 共12页

摘要： ertugliflozin or placebo. These post hoc analyses evaluated |  body weight reduction was greater with ertugliflozin | . Ertugliflozin increased the proportion of participants |  (ertugliflozin 34.9% and 13.6%, placebo 19.4% and 4.1%; odds |  ertugliflozin on HHF across BMI subgroups (Pinteraction = 0.61
关键词： body mass index |  cardiovascular and kidney outcomes |  ertugliflozin |  metabolic outcomes |  type 2 diabetes
文献传递获取全文
文献传递
收藏

2. Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial NSTL国家科技图书文献中心

Pandey, Ambarish |  Kolkailah, Ahmed A.... -  《European journal of heart failure》 - 2025,27(3) - 521～526 - 共6页

摘要：Aims In VERTIS CV, ertugliflozin was |  of ertugliflozin on the broader spectrum of all |  participants who received ertugliflozin (5 or 15 mg) were | . The effect of ertugliflozin on the first HF event |  ertugliflozin or placebo (mean follow-up 3.5 years
关键词： Heart failure |  Type 2 diabetes mellitus |  Sodium-glucose cotransporter 2 inhibitors |  Ertugliflozin |  Adjudication |  Sodium–glucose cotransporter 2 inhibitors
文献传递获取全文
文献传递
收藏

3. Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia‐associated laminitis NSTL国家科技图书文献中心

Tania Sundra |  Erin Kelty... -  《Equine Veterinary Education》 - 2025,37(4) - 202～209 - 共8页

摘要： criteria. Ertugliflozin was the most commonly prescribed | Summary Background Sodium‐glucose |  cotransporter 2 inhibitors (SGLT2i) are being used |  increasingly in equine practice. While there is emerging |  clinical evidence of the safety and efficacy of these
关键词： canagliflozin |  endocrine |  ertugliflozin |  insulin |  SGLT2 inhibitor
文献传递获取全文
文献传递
收藏

4. The Role of SGLT2 Inhibitors in Cardiovascular Management NSTL国家科技图书文献中心

Wang, Andy |  Mahmood, Uzair... -  《Cardiology in review.》 - 2025,33(1) - 22～26 - 共5页

摘要：Cardiovascular disease is a major cause of |  morbidity and mortality worldwide in patients with type 2 |  diabetes. Type 2 diabetes confers an elevated risk of |  developing heart failure and atherosclerotic cardiovascular |  disease. Until recently, there have been limited options
关键词： sodium-glucose co-transporter 2 inhibitors |  heart failure |  diabetes |  atherosclerotic cardiovascular disease |  canagliflozin |  dapagliflozin |  empagliflozin |  ertugliflozin |  sotagliflozin
文献传递获取全文
文献传递
收藏

5. SGLT2 inhibitors: how do they affect the cardiac cells NSTL国家科技图书文献中心

Erdogan, Betul Rabia |  Arioglu-Inan, Ebru -  《Molecular and Cellular Biochemistry》 - 2025,480(3) - 1359～1379 - 共21页

摘要：, and ertugliflozin) have become widely used. Unlike | The first sodium-glucose cotransporter-2 |  inhibitor (SGLT2I), canagliflozin, was approved by the U.S | . Food and Drug Administration for the treatment of |  type 2 diabetes in 2013. Since then, other members of
关键词： Apoptosis |  Cardiac cells |  Fibrosis |  Inflammation |  Ion transport |  SGLT2 inhibitors
文献传递获取全文
文献传递
收藏

6. Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond NSTL国家科技图书文献中心

Pratikeswar Panda |  Rajaram Mohapatra... -  《Current drug research reviews.》 - 2025,17(1) - 19～32 - 共14页

摘要： drugs, including canagliflozin, ertugliflozin | SGLT2 (Sodium-Glucose Co-transporter 2 | ) inhibitors, also known as gliflozin class, are a novel |  family of oral drugs being used to treat type 2 |  diabetes. SGLT2 inhibitors can work alone or in
关键词： SGLT2 inhibitors |  type 2 diabetes |  hypoglycaemia |  urinary tract infections |  diabetic ketoacidosis |  lower limb amputation |  fractures.
文献传递获取全文
文献传递
收藏

7. Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial NSTL国家科技图书文献中心

Kang, Duk-Hyun |  Park, Sung-Ji... -  《Circulation: An Official Journal of the American Heart Association》 - 2024,149(24) - 1865～1874 - 共10页 - 被引量：2

摘要： the efficacy of ertugliflozin for reduction of |  (Ertugliflozin for Functional Mitral Regurgitation) was a |  inhibitor ertugliflozin is effective for improving MR in |  ertugliflozin or placebo in addition to guideline-directed |  was significantly greater in the ertugliflozin group
关键词： clinical trial |  heart failure |  mitral valve insufficiency |  sodium-glucose transporter 2 inhibitors |  ECHOCARDIOGRAPHY |  DYSFUNCTION |  MANAGEMENT |  REPAIR
文献传递获取全文
文献传递
收藏

8. Oral sugar test responses to ertugliflozin in ten horses with insulin dysregulation NSTL国家科技图书文献中心

Tania Sundra |  Gabriele Rossi... -  《Equine Veterinary Education》 - 2024,36(6) - 317～324 - 共8页 - 被引量：1

摘要： indicates that ertugliflozin benefits horses and ponies |  effects of ertugliflozin on the results of the oral |  report the effects of ertugliflozin on responses to the |  days of treatment with 0.05 mg/kg ertugliflozin PO |  with ertugliflozin relative to pre‐treatment values
关键词： horse |  endocrine |  equine metabolic syndrome |  laminitis |  obesity |  sodium‐glucose cotransporter 2 inhibitor
文献传递获取全文
文献传递
收藏

9. Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV NSTL国家科技图书文献中心

Vikas S. Sridhar |  Francesco Cosentino... -  《Diabetes, obesity & metabolism.》 - 2024,26(11) - 5336～5346 - 共11页

摘要： effects of ertugliflozin on serum uric acid (UA) and | , ertugliflozin 5?mg or ertugliflozin 15?mg. Mean UA over time |  (260?weeks) was evaluated for pooled ertugliflozin |  ertugliflozin on a composite of gout onset or initiation of |  the placebo and ertugliflozin groups, respectively
关键词： clinical trial |  diabetic nephropathy |  inflammation |  phase III trial |  SGLT2 inhibitor |  type 2 diabetes mellitus
文献传递获取全文
文献传递
收藏

10. Urinary tract infections and genital mycotic infections associated with SGLT-2 inhibitors: an analysis of the FDA Adverse Event Reporting System NSTL国家科技图书文献中心

Yang, Ting |  Zhou, Ying... -  《Expert opinion on drug safety》 - 2024,23(7/12) - 1035～1040 - 共6页

摘要：, empagliflozin, and ertugliflozin. Risk of urinary tract |  canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin | BackgroundSodium-glucose cotransporter-2 (SGLT | -2) inhibitors are a class of antihyperglycemic |  agents, including canagliflozin, dapagliflozin
关键词： Adverse event reporting system |  disproportionality analysis |  genital mycotic infections |  SGLT-2 inhibitors |  urinary tract infections
文献传递获取全文
文献传递
收藏

相关推荐

检索结果集分析
检索结果集分析
结构化综述分析
检索条件ertugliflozin

  • 检索词扩展

NSTL主题词

  • NSTL学科导航

服务站

成员单位

友情链接

NSTL官方微信

官方微信

NSTL安卓APP

安卓APP

服务热线：

4008-161-200 800-990-8900

国家科技图书文献中心

国家科技图书文献中心

京ICP备10027328号

© Copyright(C)2023 NSTL.All Rights Reserved 版权所有

杭州服务站

0571-85112211；0571-85058943zj85112211@163.com

地址：浙江省杭州市滨江区信诚路572号 科技大市场A座318室

页面总访问量：32452656